SFigure 1

A



FP data	Mean % Inhibition	SD	SEM	n
cIAP1	97% at 12 nM	10%	3%	11
XIAP BIR3	61% at 40 nM	9%	3%	11

B



Cell Line	Mean EC_{50} (nM)	SD	SEM	n
EVSA-T	0.9	0.3	0.1	15
MDA-MB-231	4.4	2.0	0.5	15

C



SFigure 1 – (**A**) Affinity of AT-IAP for cIAP1 and XIAP as assessed by fluorescent polarization assays. **(B)** IC50 doses of AT-IAP in MDA-MB-231 and EVSA-T cells as assessed in proliferation assays. **(C)** Western blot analysis of FLIP in REN, H28, MM98, JU77 and MDA-MB-231 cells.

SFigure 2





Sfigure 2 - A) Western blot analysis of cIAP1, cIAP2, XIAP, FLIP(S), FLIP(L) and procaspase-8 following treatment with 10μM AT-IAP for 1, 3, 6, 10 and 24h in (i)H28, (ii)JU77 and (iii) MM98 cell lines. (**B**) Quantitative RT-PCR assessment of TNFα, FLIP(S), FLIP(L), cIAP1 and cIAP2 mRNA expression in H28, JU77 and MM98 cell lines following treatment with 10μM AT-IAP for 10h.

SFigure 2 Cont.



Sfigure 2 Cont (C) Western blot analysis of cIAP1 expression following treatment of the H28, JU77 and MM98 cell lines with 10μM, 1μM, 0.1μM, 10nM and 1nM AT-IAP for 24h.

SFigure 3



SFigure 3 – (**A**) Western blot analysis of (i) cIAP1, (ii) XIAP (iii) cIAP2 expression in MM98, H28, JU77 and REN cells transfected with 10nM scrambled control (SCR) or (i) cIAP1, (ii) XIAP (iii) cIAP2 siRNA for 48h. (**B**) Western blot analysis of c-FLIP expression in (i) MM98 (ii) H28 and (iii) JU77 cells transfected with 10nM scrambled control (SCR), FLIP(S), FLIP(L) and FLIP(T) siRNA for 48h.



SFigure 4



SFigure 4 – (**A**) Western blot analysis of RIPK1 and caspase 8 expression following caspase 8 immunoprecipitation (IP) in REN cells treated with 10μM AT-IAP, 10ng/mLTNFα or a combination of AT-IAP and TNFα for 6h in the presence of 10μM z-VAD-fmk. IgG isotype control antibody was used as an IP control. (**B**) Western blot analysis of RIPK1 and caspase 8 following caspase 8 IP in REN cells treated with scrambled control (SCR) or FADD (siFD) siRNA for 48h. Cells were treated with combination of 10μM AT-IAP and 10ng/mL TNFα for 6h in presence of 10μM z-VAD-fmk. IgG isotype control antibody was used as an IP control.

SFigure 4 cont.



SFigure 4 cont (**C**) Western blot analysis of RIPK1 and caspase 8 following caspase 8 IP in MM98 cells transfected with 10nM scrambled control (SCR) or a dual FLIP splice form-targeting siRNA FLIP(T) siRNA for 48h. Cells were treated with combination of 10μM AT-IAP and 10ng/mL TNFα for 6h in presence of 10μM z-VAD-fmk. (**D**) Western blot analysis of FLIP in control (EV), FLIP(S) wild-type (FS WT) and FLIP(S) F114A (FS F114A) overexpressing cell lines following transfection for 48h with 10nM scrambled control (SCR) or FLIP 5'UTR-targeting siRNA (5'UTR FLIPsi).

SFigure 5





SFigure 5 – (**A**) Caspase 8 activity assay in REN, MM98, JU77 and H28 cells following treatment with 10μM AT-IAP, 10ng/mL TNFα or a combination of AT-IAP and TNFα for 3h following transfection with 10nM scrambled control (SCR) or FLIP siRNA for 48h. (**B**) Caspase 3/7 activity assay in REN, MM98, JU77 and H28 cells following treatment with 10μM AT-IAP, 10ng/mL TNFα or a combination of AT-IAP and TNFα for 3h following transfection with 10nM scrambled control (SCR) or FLIP siRNA for 48h. **(C)** Western blot analysis of FLIP expression in MM98, H28, JU77 and REN cells transfected with 10nM scrambled control (SCR) or FLIP siRNA for 48h.

SFigure 6



SFigure 6 - Cell viability assays in (i) MM98, (ii) H28 and (iii) JU77 cells pretreated with 0.5, 1, 2.5 and 5μM SAHA for 12h prior to treatment with 10μM AT-IAP, 10ng/mL TNFα or a combination of AT-IAP and TNFα for 48h.